摘要
左乙拉西坦(levetiracetam,LEV)为吡拉西坦的类似物,是一种具有全新抗癫痫作用机制的新型抗癫痫药物,口服吸收迅速完全,血浆药物浓度达峰时间为0.6～1.3h,不受食物影响,血浆蛋白结合率低,药动学呈线性清除,不经过肝脏代谢,以原型由肾脏排出,对肝药酶无抑制或诱导作用,与其他药物之间相互影响小。在近年来国内外的临床应用中,左乙拉西坦表现出确切的抗癫痫疗效和很好的耐受性,除用于难治性癫痫的辅助治疗之外,其适应证也逐渐扩展到新诊断癫痫的单药治疗和外科术后癫痫发作的预防领域,有广阔的应用前景。
Levetiracetam,an analogue of piracetam,is one of the newer antiepileptic drugs with unique mechanism.Levetiracetam is rapidly and almost completely absorbed after oral administration and peak plasma concentration are usually achieved within 0.6-1.3 hours.The extent of bioavailability of levetiracetam is not affected by food.Levetiracetam is less than 10% bound to plasma proteins.Plasma half-life of levetiracetam is approximately 6-8 hours.Independent on hepatic enzyme system,eliminated as prototype from kidney is the major metabolism way of LEV.The exact effectiveness and good tolerance of LEV were confirmed and revealed in recent clinical trials.Besides adjunctive therapy to refractory seizures,LEV has been used as mono-drug for newly diagnosed seizures and the prevention of postoperative seizures.The prospect of LEV application should be paid more and more attention in antiepileptic therapy.
出处
《中国神经肿瘤杂志》
2010年第2期120-123,共4页
Chinese Journal of Neuro-Oncology
